期刊文献+

MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease 被引量:10

MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease
下载PDF
导出
摘要 Non-alcoholic fatty liver disease(NAFLD) is a multi-faceted condition including simple steatosis alone or associated with inflammation and ballooning(non-alcoholic steatohepatitis) and eventually fibrosis.The NAFLD incidence has increased over the last twenty years becoming the most frequent chronic liver disease in industrialized countries.Obesity,visceral adiposity,insulin resistance,and many other disorders that characterize metabolic syndrome are the major predisposing risk factors for NAFLD.Furthermore,different factors,including genetic background,epigenetic mechanisms and environmental factors,such as diet and physical exercise,contribute to NAFLD development and progression.Several lines of evidence demonstrate that specific microRNAs expression profiles are strongly associated with several pathological conditions including NAFLD.In NAFLD,microRNA deregulation in response to intrinsic genetic or epigenetic factors or environmental factors contributes to metabolic dysfunction.In this review we focused on microRNAs role both as controlled and controllers molecules in NAFLD development and/or their eventual value as non-invasive biomarkers of disease. Non-alcoholic fatty liver disease (NAFLD) is a multi-faceted condition including simple steatosis alone or associated with inflammation and ballooning (non-alcoholic steatohepatitis) and eventually fibrosis. The NAFLD incidence has increased over the last twenty years becoming the most frequent chronic liver disease in industrialized countries. Obesity, visceral adiposity, insulin resistance, and many other disorders that characterize metabolic syndrome are the major predisposing risk factors for NAFLD. Furthermore, different factors, including genetic background, epigenetic mechanisms and environmental factors, such as diet and physical exercise, contribute to NAFLD development and progression. Several lines of evidence demonstrate that specific microRNAs expression profiles are strongly associated with several pathological conditions including NAFLD. In NAFLD, microRNA deregulation in response to intrinsic genetic or epigenetic factors or environmental factors contributes to metabolic dysfunction. In this review we focused on microRNAs role both as controlled and controllers molecules in NAFLD development and/or their eventual value as non-invasive biomarkers of disease.
出处 《World Journal of Gastroenterology》 SCIE CAS 2014年第41期15079-15086,共8页 世界胃肠病学杂志(英文版)
关键词 Liver steatosis FIBROSIS Non-alcoholic fatty liver disease Non-alcoholic steatohepatitis MICRORNAS Liver steatosis Fibrosis Non-alcoholic fatty liver
  • 相关文献

参考文献11

  • 1Valerio Nobili,Anna Alisi,Massimiliano Raponi.Pediatric non-alcoholic fatty liver disease:Preventive and therapeutic value of lifestyle intervention[J].World Journal of Gastroenterology,2009,15(48):6017-6022. 被引量:5
  • 2Hisamitsu Miyaaki,Tatsuki Ichikawa,Yasuhiro Kamo,Naota Taura,Takuya Honda,Hidetaka Shibata,Maddalena Milazzo,Francesca Fornari,Laura Gramantieri,Luigi Bolondi,Kazuhiko Nakao.Significance of serum and hepatic micro RNA ‐122 levels in patients with non‐alcoholic fatty liver disease[J].Liver Int.2014(7)
  • 3Sung‐E Choi,Ting Fu,Sunmi Seok,Dong‐Hyun Kim,Eunkyung Yu,Kwan‐Woo Lee,Yup Kang,Xiaoling Li,Byron Kemper,Jongsook K. Kemper.Elevated micro RNA ‐34a in obesity reduces NAD <sup>+</sup> levels and SIRT 1 activity by directly targeting NAMPT[J].Aging Cell.2013(6)
  • 4K. H. Williams,N. A. Shackel,M. D. Gorrell,S. V. McLennan,S. M. Twigg.Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo[J].Endocrine Reviews.2013(1)
  • 5Hiroya Yamada,Koji Suzuki,Naohiro Ichino,Yoshitaka Ando,Akira Sawada,Keisuke Osakabe,Keiko Sugimoto,Koji Ohashi,Ryouji Teradaira,Takashi Inoue,Nobuyuki Hamajima,Shuji Hashimoto.Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver[J].Clinica Chimica Acta.2013
  • 6Samuele De Minicis,Chris Day,Gianluca Svegliati-Baroni.From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights[J].Current Pharmaceutical Design.2013(29)
  • 7Jiang Li,Mohammed Ghazwani,Yifei Zhang,Jianqin Lu,Jilong Li,Jie Fan,Chandrashekhar R. Gandhi,Song Li.miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression[J].Journal of Hepatology.2012
  • 8Valerio Nobili,Gianluca Svegliati-Baroni,Anna Alisi,Luca Miele,Luca Valenti,Pietro Vajro.A 360-Degree Overview Of Paediatric Nafld: Recent Insights[J].Journal of Hepatology.2012
  • 9Mahboob Hussain.Micro-RNAs (miRNAs): genomic organisation, biogenesis and mode of action[J].Cell and Tissue Research.2012(2)
  • 10.MiRs with a Sweet Tooth[J].Cell Metabolism.2011(2)

二级参考文献1

共引文献15

同被引文献158

引证文献10

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部